Welcome to the UPF Digital Repository

A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia

Show simple item record

dc.contributor.author Gómez-Zorrilla, Silvia
dc.contributor.author Sendra, Elena
dc.contributor.author Horcajada Gallego, Juan Pablo
dc.date.accessioned 2023-02-08T08:48:46Z
dc.date.available 2023-02-08T08:48:46Z
dc.date.issued 2022
dc.identifier.citation Gómez-Zorrilla S, Sendra E, Horcajada JP. A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia. Expert Rev Clin Pharmacol. 2022 Jun; 15(6): 671-88. DOI: 10.1080/17512433.2022.2100346
dc.identifier.issn 1751-2433
dc.identifier.uri http://hdl.handle.net/10230/55675
dc.description.abstract Introduction: community-acquired bacterial pneumonia (CABP) is the most common infectious cause of hospital admission in adults, and poses a significant clinical and economic burden. At the same time, antimicrobial resistance is increasing worldwide with only a few new antibiotics developed in recent years. Delafloxacin is an anionic fluoroquinolone available in intravenous and oral formulations and with a broad spectrum of activity targeting Gram-positives, including methicillin-resistant Staphylococcus aureus (MRSA), gram-negative organisms, and atypical and anaerobic organisms. It also has a better adverse event profile compared to other fluoroquinolones. Areas covered: this article reviews the current epidemiology of CABP, etiologic agents and current resistance rates, current treatment guidelines, characteristics of delafloxacin (chemistry, microbiology, PK/PD), clinical efficacy and safety in pneumonia and other indications, and regulatory affairs. Expert opinion: delafloxacin's susceptibility profile against respiratory pathogens, bioequivalent intravenous and oral formulations and favorable safety profile, support its use for the treatment of CABP. It could be useful as empirical treatment in countries with high rates of penicillin-resistant S. pneumoniae and in patients with suspected or documented pneumonia due to MRSA. In post-influenza staphylococcal bacterial pneumonia, MRSA could be also considered an important pathogen.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Taylor & Francis
dc.rights © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.title A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1080/17512433.2022.2100346
dc.subject.keyword Antimicrobial resistance
dc.subject.keyword MRSA
dc.subject.keyword Community acquired pneumonia
dc.subject.keyword Delafloxacin
dc.subject.keyword Efficacy
dc.subject.keyword Safety
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking